PLACEBO Beat Both Zyprexa & Eli Lilly's Experimental Drug

[Guest guest]

ALLIANCE FOR HUMAN RESEARCH PROTECTION Promoting Openness, Full Disclosure, and Accountabilityhttp://www.ahrp.org  and http://ahrp.blogspot.com FYIReuters reported that the results of an Eli Lilly controlled clinical trialcomparing the company's experimental antipsychotic (mGIu2/3), against itsFDA-approved blockbuster drug, Zyprexa, show that the PLACEBO PERFORMEDBETTER than EITHER of Lilly's antipsychotics.Lilly acknowledged that three patients on the experimental drug "experiencedconvulsions."..."patients given a placebo demonstrated a response that was about doublethat historically seen in clinical trials with patients suffering fromschizophrenia."The results suggest that the truth may have escaped the usual exclusioncriteria. Underlying the commercial success of the new antipsychotics isevidence (usually suppressed) showing that these drugs are both harmful andineffective even for their approved use.Lilly attempted to spin the embarrassing results, claiming the trial was"inconclusive." The company resorted to the scientifically untenable claim that Zyprexa is"known to be more effective...."    "neither its experimental drug, known as mGlu2/3, nor its antipsychoticZyprexa --known to be more effective than a placebo -- performed better thanthe placebo....patients given a placebo demonstrated a response that wasabout double that historically seen in clinical trials with patientssuffering from schizophrenia."The company claim and the experimental drug was "generally welltolerated..." is belied by three patients who had convulsions!Contact: Vera Hassner Sharavveracare212-595-8974http://www.reuters.com/article/rbssHealthcareNews/idUSN2930638220090329Reuters--Dallas News Eli Lilly schizophrenia drug trial inconclusiveSun Mar 29, 2009 * Lilly calls schizophrenia drug study inconclusive* Says placebo response was double usual response* Says to continue development of drugNEW YORK, March 29 (Reuters) - Eli Lilly and Co  Research<http://www.reuters.com/stocks/researchReports?symbol=LLY.N> said on Sundayit will initiate another mid-stage trial to study an experimentalschizophrenia drug after results from its initial Phase II trial wereinconclusive.The drugmaker said inconclusive trial results are common in the field ofneuroscience, and that it will continue developing the drug with anadditional Phase II study.In its study, Eli Lilly said patients given a placebo demonstrated aresponse that was about double that historically seen in clinical trialswith patients suffering from schizophrenia.Therefore, neither its experimental drug, known as mGlu2/3, nor itsantipsychotic Zyprexa -- known to be more effective than a placebo --performed better than the placebo.Lilly said the experimental drug was generally well-tolerated, though threepatients experienced convulsions. It also said the experimental drug had alow association with adverse events commonly associated with currentlyavailable antipsychotics, such as weight gain. (Reporting by MartinneGeller, editing by Maureen Bavdek) C Thomson Reuters 2009. All rights reserved. Thomson Reuters journalists are subject to an Editorial Handbook whichrequires fair presentation and disclosure of relevant interests.FAIR USE NOTICE: This may contain copyrighted (C ) material the use of whichhas not always been specifically authorized by the copyright owner. Suchmaterial is made available for educational purposes, to advanceunderstanding of human rights, democracy, scientific, moral, ethical, andsocial justice issues, etc. It is believed that this constitutes a 'fairuse' of any such copyrighted material as provided for in Title 17 U.S.C.section 107 of the US Copyright Law. This material is distributed withoutprofit._____________Infomail1 mailing listto send a message to Infomail1-leave =====In accordance with Title 17 U.S.C. Section 107, this material is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes.

[Guest guest]

ALLIANCE FOR HUMAN RESEARCH PROTECTION Promoting Openness, Full Disclosure, and Accountabilityhttp://www.ahrp.org and http://ahrp.blogspot.com FYIReuters reported that the results of an Eli Lilly controlled clinical trialcomparing the company's experimental antipsychotic (mGIu2/3), against itsFDA-approved blockbuster drug, Zyprexa, show that the PLACEBO PERFORMEDBETTER than EITHER of Lilly's antipsychotics.Lilly acknowledged that three patients on the experimental drug "experiencedconvulsions."..."patients given a placebo demonstrated a response that was about doublethat historically seen in clinical trials with patients suffering fromschizophrenia."The results suggest that the truth may have escaped the usual exclusioncriteria. Underlying the commercial success of the new antipsychotics isevidence (usually suppressed) showing that these drugs are both harmful andineffective even for their approved use.Lilly attempted to spin the embarrassing results, claiming the trial was"inconclusive." The company resorted to the scientifically untenable claim that Zyprexa is"known to be more effective...." "neither its experimental drug, known as mGlu2/3, nor its antipsychoticZyprexa --known to be more effective than a placebo -- performed better thanthe placebo....patients given a placebo demonstrated a response that wasabout double that historically seen in clinical trials with patientssuffering from schizophrenia."The company claim and the experimental drug was "generally welltolerated..." is belied by three patients who had convulsions!Contact: Vera Hassner Sharavveracare212-595-8974http://www.reuters.com/article/rbssHealthcareNews/idUSN2930638220090329Reuters--Dallas News Eli Lilly schizophrenia drug trial inconclusiveSun Mar 29, 2009 * Lilly calls schizophrenia drug study inconclusive* Says placebo response was double usual response* Says to continue development of drugNEW YORK, March 29 (Reuters) - Eli Lilly and Co Research<http://www.reuters.com/stocks/researchReports?symbol=LLY.N> said on Sundayit will initiate another mid-stage trial to study an experimentalschizophrenia drug after results from its initial Phase II trial wereinconclusive.The drugmaker said inconclusive trial results are common in the field ofneuroscience, and that it will continue developing the drug with anadditional Phase II study.In its study, Eli Lilly said patients given a placebo demonstrated aresponse that was about double that historically seen in clinical trialswith patients suffering from schizophrenia.Therefore, neither its experimental drug, known as mGlu2/3, nor itsantipsychotic Zyprexa -- known to be more effective than a placebo --performed better than the placebo.Lilly said the experimental drug was generally well-tolerated, though threepatients experienced convulsions. It also said the experimental drug had alow association with adverse events commonly associated with currentlyavailable antipsychotics, such as weight gain. (Reporting by MartinneGeller, editing by Maureen Bavdek) C Thomson Reuters 2009. All rights reserved. Thomson Reuters journalists are subject to an Editorial Handbook whichrequires fair presentation and disclosure of relevant interests.FAIR USE NOTICE: This may contain copyrighted (C ) material the use of whichhas not always been specifically authorized by the copyright owner. Suchmaterial is made available for educational purposes, to advanceunderstanding of human rights, democracy, scientific, moral, ethical, andsocial justice issues, etc. It is believed that this constitutes a 'fairuse' of any such copyrighted material as provided for in Title 17 U.S.C.section 107 of the US Copyright Law. This material is distributed withoutprofit.«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤«¤»¥«¤»§«¤»¥«¤»§«¤»§ - PULSE ON 21st CENTURY ALTERNATIVE MEDICINE! §Subscribe send email to: - «¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤«¤»¥«¤»§«¤»¥«¤»§«¤»GREAT VACATION RENTAL ON THE LAKE: www.vacationhomerentals.com/39833